New research generated from the Pulmonary Fibrosis Foundation Patient Registry examined racial and age differences of patients with pulmonary fibrosis, potential new clinical phenotypes, cough as a predictor of disease severity, and the effects of anticoagulation therapy on survival in interstitial lung disease.
The Pulmonary Fibrosis Foundation (PFF) Patient Registry is now a significant resource designed to promote research and accelerate treatments for pulmonary fibrosis. Registry statistics are providing scientists with a better understanding of the PF patient profile, disease progression, and effectiveness of therapies. To date, 23 studies, including abstracts and manuscripts, have been developed or are underway using PFF Registry data. Collectively, this represents $30 million in disease research
The PFF Patient Registry, initiated in 2016, is now a significant resource designed to promote research and accelerate the treatments for pulmonary fibrosis. Registry statistics are providing scientists with a better understanding of the PF patient profile, disease progression, and effectiveness of therapies.
To date, 23 studies, including abstracts and manuscripts, have been developed or are underway using PFF Registry data. Collectively, this represents $30 million in disease research.
Studies presented at ATS were developed in conjunction with investigators at leading medical centers in the PFF Care Center Network (CCN). More than 2,000 patients are enrolled in the Registry through 42 CCN sites nationwide.
“The PFF Patient Registry is an incredibly powerful research tool,” said Dr. Kevin Flaherty, Chairman of the PFF Care Center Network and PFF Patient Registry Steering Committee. “Using Registry data, biosamples and images, scientists can benchmark care and draw conclusions about how pulmonary fibrosis affects individuals.”
